Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268831 | 1.00 | ERN1 (0.41) | ERN1CYP3A4MAPTDGAT1ERCC1 | |
| SCHEMBL578367 | 0.84 | ERN1 (0.37) | ERN1DGAT1AR | |
| SCHEMBL28356847 | 0.84 | ERN1 (0.47) | ERN1CYP3A4MAPTERCC1ERCC4 | |
| SCHEMBL31117200 | 0.79 | ESR1 (0.34) | CYP3A4 | |
| SCHEMBL28655843 | 0.79 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL83764 | 0.78 | ERN1 (0.41) | ERN1CYP3A4MAPT | |
| SCHEMBL3967319 | 0.78 | ERN1 (0.52) | ERN1CYP3A4MAPT | |
| SCHEMBL6451077 | 0.78 | ERN1 (0.52) | ERN1CYP3A4MAPTAR | |
| SCHEMBL1591899 | 0.78 | ERN1 (0.42) | ERN1CYP3A4DGAT1 | |
| SCHEMBL23890741 | 0.75 | ERN1 (0.31) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024190777-A1 | TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024190780-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | ERN1 2044/4885CYP3A4 1111/4885MAPT 2144/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | ERN1 1445/4885CYP3A4 32/4885MAPT 3335/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | ERN1 1445/4885CYP3A4 32/4885MAPT 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.